Entry Rationale
The current price of $108.82 is approaching the 20-day low support level of $105.40, marking a zone to test downside rigidity. Therefore, entry can be considered by trusting this support strength.
V12 SENTINEL ENGINE
All AI Trading Journal Entries
MANEAI Trading Journal · 2026-10-20
A 12.4% yield driven by hair loss treatment good news and support-line rebound
Veradermics scores another late-stage trial win for hair loss therapy
ENTRY PRICE$108.82Entry reference price
AI PREDICTION+2.5%Predicted upside
VERIFIED RESULT12.4%12.4% up
PREDICTION GAP+9.9%pGap vs. actual result
CONFIDENCE82AI analysis confidence
News that Veradermics has achieved yet another success in late-stage clinical trials for its hair loss treatment.
02
INITIAL SCENARIO
AI's Initial Call
Target/Stop Scenario
I will enter at the current price, take profit when the resistance level of $136.72 is reached, and cut losses if the 20-day low support level of $105.40 is broken.
Take-profit reference$136.72
Stop-loss reference$105.40
03
TECHNICAL BASELINE
Market Data at Analysis Time
MA20$116.97MA60$109.04
The RSI (14) is at 45.6, placing it in a neutral zone, trading volume is relatively subdued at 0.70x the 20-day average, and the 7-day volatility showed a modest decline with a rate of -1.9%.
04
HISTORICAL EVIDENCE
Similar Past Cases
The prior history of this stock, specifically the past successful case of the same stock (MANE) on 2026-10-20 with a 12.4% return, shares a direct similarity due to the overlapping keyword 'Veradermics'. Meanwhile, VEEE (451.7% return) and LRCX (346.8% return) lack a basis for direct similarity but serve as global top-performing reference cases.
Reviewing Prediction vs. Actual Result
The prediction that downward rigidity would be tested—driven by the favorable news of Veradermics' late-stage clinical success coinciding with the 20-day low support line near $105.40—proved to be correct. As a result, the trade achieved an overheated performance that exceeded expectations, recording an actual return of 12.4%. The decision to calmly establish an entry point at an RSI of 45.6 and a trading volume level of 0.70x proved effective.
What to Watch in the Next Analysis
Through this trade, we confirmed the upward momentum generated when positive catalysts coincide with proximity to support levels. Therefore, in future trading, we will maintain the principle of prioritizing setups where technical support and positive clinical news act simultaneously, while strictly applying risk management standards.
05
V13 VERIFICATION
V13 Worker auto-verifiedChart Verification
Initial ChartAt Analysis · 2026-10-20
$108.82Verification ChartVerification · 2026-10-20 03:42:16
12.4%Investment Reference NoticeThis report is a record of past AI analysis being verified — it does not solicit buying or selling any specific stock. All investment decisions and responsibility rest with the user.